STATEMENT FOR IMMEDIATE RELEASE
WASHINGTON, D.C. – The House unanimously passed H.R. 6092, the “Veteran’s Prostate Cancer Treatment and Research Act,” designed to establish a national clinical pathway for prostate cancer. This standardized system of care would enhance treatment and increase access to clinical trials via a registry for the most commonly diagnosed cancer in the Veterans Health Administration.
“Our service members have dedicated their lives to the American people and they deserve to receive the same high quality care any one of us would expect when faced with a diagnosis of prostate cancer,” said Alison Manson, ZERO’s Vice President of Advocacy and Government Relations. “ZERO applauds the House of Representatives for its efforts to ensure that the nearly half a million veterans facing prostate cancer are no longer subjected to the risks of an unorganized health system.”
Congressman Neal Dunn, M.D. (FL-02), a former urologist, sponsored this effort. No timetable has been set for when the Senate may vote on the measure, but it’s expected to move quickly through the Senate.
Veterans face prostate cancer at rates that double those of civilians. For more information on ZERO’s work with veterans, visit zerocancer.org/veterans. To see previous news on this legislation, click here.
About ZERO — The End of Prostate Cancer
ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. We’re building Generation ZERO, the first generation of men free from prostate cancer, through our national run/walk series, education and patient support programs, and grassroots advocacy. ZERO is a 501(c)(3) philanthropic organization recognized with four out of four stars by Charity Navigator, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 85 cents of every dollar to research and programs. For more information, visit www.zerocancer.org.